Intech Biopharm Corporation (TPEX:6461)

Market Cap	3.23B
Revenue (ttm)	115.23M
Net Income (ttm)	-322.26M
Shares Out	162.94M
EPS (ttm)	-2.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	186,618
Average Volume	388,835
Open	20.10
Previous Close	19.80
Day's Range	19.80 - 20.10
52-Week Range	16.50 - 34.60
Beta	-0.11
RSI	49.90
Earnings Date	Aug 10, 2025

About Splunk

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 90
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6461

Financial Performance

In 2024, Intech Biopharm's revenue was 39.78 million, an increase of 53.90% compared to the previous year's 25.85 million. Losses were -368.21 million, 8.94% more than in 2023.